by Madaline Spencer | Mar 26, 2026
The US Food and Drug Administration (FDA) has approved Lynavoy (linerixibat) for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC). PBC is a chronic, progressive autoimmune liver disease in which the bile ducts become...
by Madaline Spencer | Mar 24, 2026
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for mavorixafor (Xolremdi) for the treatment of WHIM syndrome in patients aged 12 years and older. WHIM syndrome is...
by Madaline Spencer | Mar 23, 2026
Geraldine Bliss, Co-Founder and President of CureSHANK, and Jenny Graham Beeson, Board Member for CureSHANK, discuss clinical research in Phelan-McDermid syndrome (PMS) and the Start Genetic initiative. PMS is a chromosome disorder caused by deletions at...
by Madaline Spencer | Mar 20, 2026
Peng Lu, MD, PhD, Chief Medical Officer at Pharvaris, and Wim Souverijns, PhD, Chief Commercial Officer at Pharvaris, discuss the RAPIDe-3 clinical trial of deucrictibant for patients with hereditary angioedema (HAE). Hereditary angioedema (HAE) is a...
by Madaline Spencer | Mar 19, 2026
The US Food and Drug Administration (FDA) has approved Juxtapid (lomitapide) capsules for the treatment of pediatric patients ages 2 years and older with homozygous familial hypercholesterolemia (HoFH). HoFH is a condition characterized by very high levels of...
